9 news items
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
AZN
MRK
MRNA
8 May 24
. The first-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer's R&D pipeline
Merck Announces First-Quarter 2024 Financial Results
MRK
25 Apr 24
products, and the favorable impact of foreign exchange.
Non-GAAP R&D expenses were $4.0 billion
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
ABBV
ANIX
BIIB
20 Mar 24
for accelerated development of Seagen’s robust pipeline through Pfizer’s R&D, commercialization, and manufacturing prowess
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
ABBV
ANIX
BIIB
20 Mar 24
for accelerated development of Seagen’s robust pipeline through Pfizer’s R&D, commercialization, and manufacturing prowess
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
ABBV
ANIX
BIIB
20 Mar 24
for accelerated development of Seagen’s robust pipeline through Pfizer’s R&D, commercialization, and manufacturing prowess
59h34bg1x7b2ampiwq mvq2ybt0hbqpdizh1unwozvp2yqso81yfu4g
ABBV
ANIX
BIIB
20 Mar 24
robust pipeline through Pfizer's R&D, commercialization, and manufacturing prowess.
AbbVie’s
cawue5daqq31m8jrnrs6dgzcb65g91i4vlx18rcbybwwrsnx
HARP
MRK
11 Mar 24
deductible charge to R&D expense of approximately $650 million. The impact of the transaction on expected full-year non-GAAP EPS is approximately $0.26
qp7cc
ABBV
LVTX
MRK
5 Mar 24
. These are some factors driving the growth during the forecast period. Companies engaged in manufacturing cancer drugs have increased their focus on R&D activities
k590hyg3wh 7houo8d4
ALDX
LGND
MRK
27 Feb 24
expenses, partially offset by an increase in R&D expenses due to the Novan acquisition. General and administrative expenses were $52.8 million
- Prev
- 1
- Next